D.E. Shaw & Co
SGMO

D.E. Shaw & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

D.E. Shaw & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,165,993
Closed -$418K – 4845
2024
Q2 		$418K Sell
1,165,993
-1,901,442
-62% -$1.03M ﹤0.01% 3733
2024
Q1 		$2.06M Sell
3,067,435
-1,616,538
-35% -$1.17M ﹤0.01% 2612
2023
Q4 		$2.54M Buy
4,683,973
+2,175,388
+87% +$1M ﹤0.01% 2482
2023
Q3 		$1.5M Buy
2,508,585
+124,609
+5% +$133K ﹤0.01% 2801
2023
Q2 		$3.1M Buy
2,383,976
+590,789
+33% +$807K ﹤0.01% 2270
2023
Q1 		$3.16M Buy
1,793,187
+417,358
+30% +$1.19M ﹤0.01% 2336
2022
Q4 		$4.32M Buy
1,375,829
+171,197
+14% +$664K ﹤0.01% 2233
2022
Q3 		$5.9M Buy
1,204,632
+48,402
+4% +$249K 0.01% 1901
2022
Q2 		$4.79M Buy
1,156,230
+401,463
+53% +$1.74M 0.01% 2179
2022
Q1 		$4.38M Buy
754,767
+200,022
+36% +$1.19M ﹤0.01% 2464
2021
Q4 		$4.16M Buy
554,745
+512,831
+1,224% +$4.45M ﹤0.01% 2583
2021
Q3 		$378K Buy
41,914
+17,269
+70% +$171K ﹤0.01% 4240
2021
Q2 		$295K Sell
24,645
-47,063
-66% -$533K ﹤0.01% 4288
2021
Q1 		$899K Sell
71,708
-375,298
-84% -$5.06M ﹤0.01% 3197
2020
Q4 		$6.98M Buy
447,006
+303,994
+213% +$3.56M 0.01% 1617
2020
Q3 		$1.35M Buy
143,012
+108,797
+318% +$1.18M ﹤0.01% 2662
2020
Q2 		$307K Buy
34,215
+22,709
+197% +$211K ﹤0.01% 3616
2020
Q1 		$73K Buy
+11,506
New +$85.4K ﹤0.01% 3809
2019
Q2 		– Sell
-179,575
Closed -$1.91M – 3837
2019
Q1 		$1.71M Sell
179,575
-89,113
-33% -$910K ﹤0.01% 2272
2018
Q4 		$3.08M Buy
268,688
+170,876
+175% +$2.12M ﹤0.01% 1835
2018
Q3 		$1.66M Buy
97,812
+83,806
+598% +$1.27M ﹤0.01% 2337
2018
Q2 		$199K Sell
14,006
-316,135
-96% -$5.25M ﹤0.01% 3559
2018
Q1 		$6.27M Sell
330,141
-1,034,154
-76% -$22.1M 0.01% 1270
2017
Q4 		$22.4M Sell
1,364,295
-240,260
-15% -$3.57M 0.03% 634
2017
Q3 		$24.1M Buy
1,604,555
+487,033
+44% +$5.38M 0.04% 539
2017
Q2 		$9.83M Buy
1,117,522
+910,818
+441% +$5.84M 0.02% 910
2017
Q1 		$1.07M Sell
206,704
-153,334
-43% -$615K ﹤0.01% 2258
2016
Q4 		$1.1M Buy
360,038
+208,717
+138% +$760K ﹤0.01% 2400
2016
Q3 		$701K Buy
151,321
+37,915
+33% +$193K ﹤0.01% 2610
2016
Q2 		$657K Sell
113,406
-20,776
-15% -$132K ﹤0.01% 2660
2016
Q1 		$812K Sell
134,182
-322,118
-71% -$1.93M ﹤0.01% 2498
2015
Q4 		$4.17M Buy
456,300
+48,825
+12% +$376K 0.01% 1541
2015
Q3 		$2.3M Buy
407,475
+219,596
+117% +$1.81M ﹤0.01% 1993
2015
Q2 		$2.08M Sell
187,879
-213,004
-53% -$2.75M ﹤0.01% 2185
2015
Q1 		$6.29M Buy
400,883
+3,376
+0.8% +$52.2K 0.01% 1235
2014
Q4 		$6.05M Buy
397,507
+18,196
+5% +$221K 0.01% 1423
2014
Q3 		$4.09M Buy
379,311
+190,468
+101% +$2.49M 0.01% 1702
2014
Q2 		$2.88M Buy
188,843
+68,994
+58% +$993K ﹤0.01% 2020
2014
Q1 		$2.17M Buy
119,849
+87,370
+269% +$1.68M ﹤0.01% 2305
2013
Q4 		$451K Buy
32,479
+14,204
+78% +$164K ﹤0.01% 3788
2013
Q3 		$192K Buy
+18,275
New +$182K ﹤0.01% 4101

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

D.E. Shaw & Co's SGMO Position: Q3 2024 in Review

D.E. Shaw & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 1,165,993 shares — an estimated $418K sold.

D.E. Shaw & Co first reported a position in SGMO in Q3 2013 and held it in 41 quarters. The position peaked at $24.1M in Q3 2017. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • D.E. Shaw & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,165,993 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $418K.
  • D.E. Shaw & Co first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 41 quarters.
  • D.E. Shaw & Co's SANGAMO THERAPEUTICS INC position peaked at $24.1M in Q3 2017.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.